Triaziquone — predicted protein targets

Known targets — ChEMBL curated mechanism

The experimentally established mechanism targets of Triaziquone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	DNMT1	P26358	1/20	0.42

▸	MAPT	P10636	3/20	0.40

▸	HTT	P42858	2/20	0.40

▸	TP53	P04637	1/20	0.40

▸	STAT3	P40763	1/20	0.40

▸	SMN1; SMN2	Q16637	1/20	0.40

▸	NSD2	O96028	3/20	0.35

▸	APAF1	O14727	2/20	0.35

▸	TDP2	O95551	2/20	0.35

▸	HKDC1	Q2TB90	2/20	0.35

▸	KMT2A	Q03164	2/20	0.33

▸	MEN1	O00255	1/20	0.33

▸	NPC1	O15118	1/20	0.33

▸	RAB9A	P51151	1/20	0.33

▸	GALK1	P51570	1/20	0.33

▸	BLM	P54132	1/20	0.33

▸	ATM	Q13315	1/20	0.33

▸	NOD2	Q9HC29	1/20	0.33

▸	ATG4B	Q9Y4P1	1/20	0.33

▸	CYP1A2	P05177	1/20	0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Triaziquone SCHEMBL4608905	0.94	DNMT1 (0.43)	DNMT1MAPTHTTTP53STAT3
Triaziquone SCHEMBL16419	0.91	MAPT (0.42)	DNMT1MAPTHTTTP53STAT3
Triaziquone SCHEMBL11422311	0.91	MAPT (0.42)	DNMT1MAPTHTTTP53STAT3
Triaziquone SCHEMBL4334317	0.89	DNMT1 (0.40)	DNMT1MAPTHTTTP53STAT3
Triaziquone SCHEMBL738610	0.89	DNMT1 (0.42)	DNMT1MAPTHTTTP53STAT3
Triaziquone SCHEMBL9876358	0.88	DNMT1 (0.47)	DNMT1MAPTHTTTP53STAT3
Triaziquone SCHEMBL3101456	0.88	DNMT1 (0.47)	DNMT1MAPTHTTTP53STAT3
Triaziquone SCHEMBL6000230	0.88	DNMT1 (0.47)	DNMT1MAPTHTTTP53STAT3
Triaziquone SCHEMBL7088197	0.88	DNMT1 (0.47)	DNMT1MAPTHTTTP53STAT3
Triaziquone SCHEMBL5054475	0.88	DNMT1 (0.47)	DNMT1MAPTHTTTP53STAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
CN-110229189-B	Preparation method of tri-oxalic acid phosphate	上海如鲲新材料有限公司	2021-05-07	—	—	CN	claimed
US-11884647-B2	Compounds and methods for targeting pathogenic blood vessels	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US)	2024-01-30	—	—	US	disclosed
US-20210147385-A1	COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	2021-05-20	—	—	US	disclosed
WO-2021076886-A1	3-PHENYLSULPHONYL-QUINOLINE DERIVATIVES AS AGENTS FOR TREATING PATHOGENIC BLOOD VESSELS DISORDERS	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US)	2021-04-22	—	—	WO	disclosed
US-5618927-A	INCUBATION IN SOLUTION OF TRIS	BOEHRINGER MANNHEIM GMBH (DE)	1997-04-08	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-11884647-B2	Compounds and methods for targeting pathogenic blood vessels	TEK, KDR, LIPG	DNMT1 4564/4885MAPT 1494/4885HTT 2091/4885
US-20210147385-A1	COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS	TEK, KDR, LIPG	DNMT1 4564/4885MAPT 1494/4885HTT 2091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.